We are live on ! Find out more
ACM

Aquilo Capital Management Portfolio holdings

AUM $55.8M
1-Year Est. Return 41.76%
This Fund
S&P 500
This Quarter Est. Return
-8.83%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$241M
AUM Growth
-$24.9M
Cap. Flow
+$451K
Cap. Flow %
0.19%
Top 10 Hldgs %
94.79%
Holding
14
New
1
Increased
3
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$1.85M
2
SLN
Silence Therapeutics
SLN
+$331K
3
QURE icon
uniQure
QURE
+$266K

Top Sells

Rank Stock Value
1
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
+$15.3M
2
MRUS
Merus
MRUS
+$3.61M
3
ARWR icon
Arrowhead Research
ARWR
+$2.67M
4
RGNX icon
Regenxbio
RGNX
+$1.48M
5
ARVN icon
Arvinas
ARVN
+$1.42M

Sector Composition

Rank Sector Weight
1 Healthcare 70.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
1
PUT
Invesco QQQ Trust
QQQ
$481B
$70.6M 29.26%
+220,000
New +$64.9M
BPMC
2
DELISTED
Blueprint Medicines
BPMC
$28M 11.61%
622,829
+41,061
+7% +$1.85M
ARWR icon
3
Arrowhead Research
ARWR
$12.4B
$25.9M 10.72%
1,018,474
-85,041
-8% -$2.67M
MRUS
4
DELISTED
Merus
MRUS
$22.5M 9.34%
1,225,109
-207,000
-14% -$3.61M
KYMR icon
5
Kymera Therapeutics
KYMR
$8.94B
$17.8M 7.38%
601,325
-28,086
-4% -$906K
ARVN icon
6
Arvinas
ARVN
$572M
$17.2M 7.12%
628,941
-45,000
-7% -$1.42M
RGNX icon
7
Regenxbio
RGNX
$708M
$15.7M 6.51%
831,014
-66,670
-7% -$1.48M
QURE icon
8
uniQure
QURE
$3.22B
$12.8M 5.32%
637,526
+12,672
+2% +$266K
GMAB icon
9
Genmab
GMAB
$19.5B
$9.17M 3.8%
242,848
– –
ARGX icon
10
argenx
ARGX
$54.1B
$8.94M 3.71%
24,000
– –
SLN
11
Silence Therapeutics
SLN
$564M
$8.14M 3.37%
1,312,233
+28,100
+2% +$331K
PVLA
12
Palvella Therapeutics
PVLA
$2.27B
$4.44M 1.84%
56,911
– –
XBI icon
13
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-500,000
Closed -$41.5M
AMYT
14
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
– –
-2,098,993
Closed -$15.3M

Similar funds

VCM
VeriStar Capital Management New York $54.7M AUM 2.08% 1-Year Est. Return
YEPV
Yorktown Energy Partners VIII New York $52.9M AUM 30% 1-Year Est. Return
HWP
Heritage Wealth Partners Dublin, Ohio $65.6M AUM 16.69% 1-Year Est. Return
GIS
Grayhawk Investment Strategies Calgary, Alberta, Canada $43.9M AUM 6.23% 1-Year Est. Return
AA
AlphaQ Advisors Winter Park, Florida $41.7M AUM 12.96% 1-Year Est. Return
PGIM
Pacific Global Investment Management Glendale, California $70.7M AUM 14.46% 1-Year Est. Return
RGMC
Revolution Growth Management Company Washington, District of Columbia $70.8M AUM 20.1% 1-Year Est. Return
PAM
Pamalican Asset Management Hong Kong $75.4M AUM

Aquilo Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Aquilo Capital Management held 14 positions worth $241M, down 9.4% from $266M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Aquilo Capital Management's Q1 2023 filing shows 1 new, 3 increased, 5 reduced and 2 closed positions. The largest sale was Amryt Pharma plc American Depositary Shares, an estimated $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 84% a quarter earlier.

  • Aquilo Capital Management added most to Blueprint Medicines in Q1 2023, an estimated $1.85M increase.
  • Aquilo Capital Management's biggest Q1 2023 reduction was Merus, cutting an estimated $3.61M.
  • Aquilo Capital Management fully exited Amryt Pharma plc American Depositary Shares in Q1 2023, selling an estimated $15.3M.
  • Aquilo Capital Management's ten largest holdings make up 95% of its $241M portfolio in Q1 2023.
  • Aquilo Capital Management opened 1 new position and closed 2 in Q1 2023.
  • Aquilo Capital Management's portfolio value fell 9.4% quarter-over-quarter to $241M.

Based on Aquilo Capital Management's 13F filing for Q1 2023, filed 15 May 2023.